Therefore, Rasd1 may be a potential anti-inflammatory therapeutic target, which could reduce the adverse effects of dexamethasone that is widely used clinically, especially when the patients have myocardial ischemia. This evidence concerns the gene RASD1 and myocardial ischemia.